A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma

Lakshmi Rajdev, Gary Goldberg, Una Hopkins, Joseph A. Sparano

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and objective: Preclinical data suggest gemcitabine may have schedule-dependent activity favoring prolonged infusion. We sought to determine the recommended phase II dose (RPTD) and toxicity of gemcitabine when given as a continuous intravenous (CIVI) over 96 h. Patients and methods: Gemcitabine was initially given at 1 mg/m2/d for 48, then 72, and finally 96 h. The dose was then increased to 2, 4, 6, 10, 15, 20, and 25 mg/m2/d. Dose levels of 7, 8, 9 mg/m2/d as 96-h infusion were added later after a protocol modification. After identifying the RPTD using an every 3-wk schedule, we then evaluated the feasibility of repeating the infusion every 2 wk, and then weekly for 3 of 4 wk. Results: Thirty-four patients with a variety of tumor types received a total of 126 cycles of therapy (median of 2 cycles, range 1-10 cycles). The RPTD was 8 mg/m2/d every 3 wk, and 6 mg/m2/d every 2 wk. The most common grade 2 or higher toxicities at all dose levels (≥ grade 2) included fever (n = 14), dyspnea (n = 7), mucositis (n = 6), hypotension (n = 6), nausea/vomiting (n = 6), and fatigue (n = 5). Neutropenia and/or thrombocytopenia were uncommon. Conclusion: Administration of gemcitabine as a 96-h infusion results in a markedly different toxicity profile and RPTD than when given by a conventional 30-min infusion. The RPTD was 8 mg/m 2/d (32 mg/m2/course) when given every 3 wk, or 6 mg/m2/d (24 mg/m2/course) when given every 2 wk.

Original languageEnglish (US)
Pages (from-to)369-376
Number of pages8
JournalMedical Oncology
Volume23
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

gemcitabine
Intravenous Infusions
Lymphoma
Carcinoma
Appointments and Schedules
Mucositis
Neutropenia
Thrombocytopenia
Dyspnea
Hypotension
Nausea
Vomiting
Fatigue
Fever
Neoplasms

Keywords

  • 96 h
  • Gemcitabine
  • Infusional
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. / Rajdev, Lakshmi; Goldberg, Gary; Hopkins, Una; Sparano, Joseph A.

In: Medical Oncology, Vol. 23, No. 3, 09.2006, p. 369-376.

Research output: Contribution to journalArticle

@article{12a8b899f38646cebabc3b202c1acd4c,
title = "A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma",
abstract = "Background and objective: Preclinical data suggest gemcitabine may have schedule-dependent activity favoring prolonged infusion. We sought to determine the recommended phase II dose (RPTD) and toxicity of gemcitabine when given as a continuous intravenous (CIVI) over 96 h. Patients and methods: Gemcitabine was initially given at 1 mg/m2/d for 48, then 72, and finally 96 h. The dose was then increased to 2, 4, 6, 10, 15, 20, and 25 mg/m2/d. Dose levels of 7, 8, 9 mg/m2/d as 96-h infusion were added later after a protocol modification. After identifying the RPTD using an every 3-wk schedule, we then evaluated the feasibility of repeating the infusion every 2 wk, and then weekly for 3 of 4 wk. Results: Thirty-four patients with a variety of tumor types received a total of 126 cycles of therapy (median of 2 cycles, range 1-10 cycles). The RPTD was 8 mg/m2/d every 3 wk, and 6 mg/m2/d every 2 wk. The most common grade 2 or higher toxicities at all dose levels (≥ grade 2) included fever (n = 14), dyspnea (n = 7), mucositis (n = 6), hypotension (n = 6), nausea/vomiting (n = 6), and fatigue (n = 5). Neutropenia and/or thrombocytopenia were uncommon. Conclusion: Administration of gemcitabine as a 96-h infusion results in a markedly different toxicity profile and RPTD than when given by a conventional 30-min infusion. The RPTD was 8 mg/m 2/d (32 mg/m2/course) when given every 3 wk, or 6 mg/m2/d (24 mg/m2/course) when given every 2 wk.",
keywords = "96 h, Gemcitabine, Infusional, Phase I",
author = "Lakshmi Rajdev and Gary Goldberg and Una Hopkins and Sparano, {Joseph A.}",
year = "2006",
month = "9",
doi = "10.1385/MO:23:3:369",
language = "English (US)",
volume = "23",
pages = "369--376",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma

AU - Rajdev, Lakshmi

AU - Goldberg, Gary

AU - Hopkins, Una

AU - Sparano, Joseph A.

PY - 2006/9

Y1 - 2006/9

N2 - Background and objective: Preclinical data suggest gemcitabine may have schedule-dependent activity favoring prolonged infusion. We sought to determine the recommended phase II dose (RPTD) and toxicity of gemcitabine when given as a continuous intravenous (CIVI) over 96 h. Patients and methods: Gemcitabine was initially given at 1 mg/m2/d for 48, then 72, and finally 96 h. The dose was then increased to 2, 4, 6, 10, 15, 20, and 25 mg/m2/d. Dose levels of 7, 8, 9 mg/m2/d as 96-h infusion were added later after a protocol modification. After identifying the RPTD using an every 3-wk schedule, we then evaluated the feasibility of repeating the infusion every 2 wk, and then weekly for 3 of 4 wk. Results: Thirty-four patients with a variety of tumor types received a total of 126 cycles of therapy (median of 2 cycles, range 1-10 cycles). The RPTD was 8 mg/m2/d every 3 wk, and 6 mg/m2/d every 2 wk. The most common grade 2 or higher toxicities at all dose levels (≥ grade 2) included fever (n = 14), dyspnea (n = 7), mucositis (n = 6), hypotension (n = 6), nausea/vomiting (n = 6), and fatigue (n = 5). Neutropenia and/or thrombocytopenia were uncommon. Conclusion: Administration of gemcitabine as a 96-h infusion results in a markedly different toxicity profile and RPTD than when given by a conventional 30-min infusion. The RPTD was 8 mg/m 2/d (32 mg/m2/course) when given every 3 wk, or 6 mg/m2/d (24 mg/m2/course) when given every 2 wk.

AB - Background and objective: Preclinical data suggest gemcitabine may have schedule-dependent activity favoring prolonged infusion. We sought to determine the recommended phase II dose (RPTD) and toxicity of gemcitabine when given as a continuous intravenous (CIVI) over 96 h. Patients and methods: Gemcitabine was initially given at 1 mg/m2/d for 48, then 72, and finally 96 h. The dose was then increased to 2, 4, 6, 10, 15, 20, and 25 mg/m2/d. Dose levels of 7, 8, 9 mg/m2/d as 96-h infusion were added later after a protocol modification. After identifying the RPTD using an every 3-wk schedule, we then evaluated the feasibility of repeating the infusion every 2 wk, and then weekly for 3 of 4 wk. Results: Thirty-four patients with a variety of tumor types received a total of 126 cycles of therapy (median of 2 cycles, range 1-10 cycles). The RPTD was 8 mg/m2/d every 3 wk, and 6 mg/m2/d every 2 wk. The most common grade 2 or higher toxicities at all dose levels (≥ grade 2) included fever (n = 14), dyspnea (n = 7), mucositis (n = 6), hypotension (n = 6), nausea/vomiting (n = 6), and fatigue (n = 5). Neutropenia and/or thrombocytopenia were uncommon. Conclusion: Administration of gemcitabine as a 96-h infusion results in a markedly different toxicity profile and RPTD than when given by a conventional 30-min infusion. The RPTD was 8 mg/m 2/d (32 mg/m2/course) when given every 3 wk, or 6 mg/m2/d (24 mg/m2/course) when given every 2 wk.

KW - 96 h

KW - Gemcitabine

KW - Infusional

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=33749379982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749379982&partnerID=8YFLogxK

U2 - 10.1385/MO:23:3:369

DO - 10.1385/MO:23:3:369

M3 - Article

C2 - 17018894

AN - SCOPUS:33749379982

VL - 23

SP - 369

EP - 376

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 3

ER -